Table 1.
Association between CD44 variant 6 (CD44v6) expression pattern and clinicopathological characteristics in patients with stage III–IV ovarian cancer
| All cases, n (%) | CD44v6-high group, n (%) | CD44v6-low group, n (%) | P-value | |
|---|---|---|---|---|
| All cases | 59 | 13 | 46 | |
| Median age, years (range) | 57 (37–82) | 59 (43–82) | 56 (37–77) | 0.84 |
| Age, years | ||||
| <50 | 18 (30.5) | 3 (23.1) | 15 (32.6) | 0.51 |
| ≥50 | 41 (69.5) | 10 (76.9) | 31 (67.4) | |
| Histological type | ||||
| Serous | 42 (71.2) | 7 (53.8) | 35 (76.1) | 0.12 |
| Clear | 3 (5.1) | 2 (15.4) | 1 (2.2) | |
| Endometrioid | 5 (8.5) | 1 (7.7) | 4 (8.7) | |
| Mucinous | 1 (1.7) | 1 (7.7) | 0 (0.0) | |
| Mixed | 7 (11.8) | 1 (7.7) | 6 (13.0) | |
| Undifferentiated | 1 (1.7) | 1 (7.7) | 0 (0.0) | |
| CA125, U/mL | ||||
| <500 | 18 (30.5) | 6 (46.2) | 12 (26.1) | 0.16 |
| ≥500 | 41 (69.5) | 7 (53.8) | 34 (73.9) | |
| Tumor size, cm | ||||
| <10 | 40 (67.8) | 7 (53.8) | 33 (71.7) | 0.22 |
| ≥10 | 19 (32.2) | 6 (46.2) | 13 (28.3) | |
| First-line chemotherapy regmen | ||||
| Paclitaxel/carboplatin | 57 (96.6) | 12 (92.3) | 45 (97.8) | 0.33 |
| Other | 2 (3.4) | 1 (7.7) | 1 (2.2) | |
| No. of cycles of chemotherapy | ||||
| <2 | 41 (69.5) | 8 (61.5) | 33 (71.7) | 0.48 |
| ≥3 | 18 (30.5) | 5 (38.5) | 13 (28.3) | |